Aster DM Quality Care merger scales hospital network and supports margin growth

Investment View and Merger Rationale

In its September 2026 initiating-coverage report, Motilal Oswal Financial Services Limited initiated coverage of Aster DM Quality Care with a Buy rating. The broker’s investment case centres on the transformative merger of Aster DM Healthcare and Quality Care India Limited (QCIL), which has created one of India’s three largest hospital platforms.

The combined entity operates 39 hospitals across 28 cities with around 10,900 capacity beds. It plans to add more than 4,150 beds, taking total capacity above 15,000 beds by FY30.

Cluster-Led Platform and Operating Synergies

Motilal Oswal views the combined platform’s cluster-led model as a key advantage. Kerala is a mature and high-margin base, while Karnataka, Maharashtra, Andhra Pradesh and Telangana provide a longer growth runway.

The merger adds the CARE Hospitals, KIMSHEALTH and Evercare networks, broadens geographic coverage and should improve cross-cluster referrals, procurement scale and clinician utilisation. The broker expects the following initiatives to generate operating synergies:

• Centralised procurement and supply-chain optimisation.
• Sharing of clinical resources.
• Corporate-cost rationalisation.

A higher share of complex specialties, including oncology, cardiac sciences, neurosciences and transplants, together with medical value travel, should support revenue per occupied bed growth.

Recent Financial and Operating Performance

Standalone Aster DM Healthcare recorded revenue of Rs 4,640 crore in FY26, up 12 per cent year on year. Operating EBITDA margin expanded to 20.4 per cent from 19.5 per cent in FY25, while revenue per occupied bed rose from Rs 36,500 in FY23 to Rs 51,800 in FY26.

In 1QFY27, the combined platform reported revenue of Rs 2,600 crore, up 20 per cent year on year, and EBITDA of Rs 580 crore, up 30 per cent year on year. EBITDA margin improved 170 basis points to 22.2 per cent, patient volumes grew 13 per cent and occupancy increased 510 basis points to 64 per cent.

Mature hospitals contributed around 65 per cent of 1QFY27 revenue and delivered a 29.7 per cent EBITDA margin, while emerging hospitals grew revenue 63 per cent year on year.

Financial Outlook

On a pro forma basis, the merged entity generated FY26 revenue of Rs 9,270 crore and EBITDA of about Rs 2,000 crore, representing growth of 14 per cent and 21 per cent respectively. Motilal Oswal forecasts revenue, EBITDA and profit after tax to grow at compound annual growth rates of 19.5 per cent, 25 per cent and 33 per cent over FY26-FY28.

The broker expects EBITDA margin to expand from 21.2 per cent in FY26 to 23.2 per cent in FY28, driven by synergies, occupancy gains, higher asset utilisation and a better case mix. It forecasts return on equity to improve from 10.5 per cent in FY26 to 15.9 per cent in FY28.

Valuation and Target Price

Motilal Oswal values Aster DM Quality Care at 27 times 12-month forward EBITDA of Rs 2,767 crore, adjusted for minority interest, to derive a target price of Rs 910. This implies 20 per cent upside from Rs 759.

The broker considers the stock’s discount to premium hospital peers justified partly by its earlier stage of integration. However, it sees scope for the gap to narrow if synergies, margins, returns and the expansion pipeline are delivered.

Key Risks

• Delayed QCIL integration and realisation of synergies.
• Delays in commissioning or ramping up new beds.
• Healthcare price caps or changes in reimbursement.
• Competition in core clusters.
• Employee-cost inflation.
• Non-compliance with healthcare regulations.